- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6 result(s) found for: Tissue Transglutaminase.
Displaying page 1 of 1.
EudraCT Number: 2022-001656-41 | Sponsor Protocol Number: TCeD21 | Start Date*: 2022-12-07 |
Sponsor Name:Topas Therapeutics GmbH | ||
Full Title: A double-blind, randomized, placebo-controlled, phase 2a study to evaluate the safety, tolerability, and pharmacodynamic (PD) effects of two infusions of escalating doses of TPM502 in adults diagno... | ||
Medical condition: Coeliac disease | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NO (Ongoing) FI (Ongoing) DE (Ongoing) NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-001678-10 | Sponsor Protocol Number: NL65853.029.18 | Start Date*: 2019-06-06 |
Sponsor Name:VU Medical Center | ||
Full Title: Tofacitinib: salvage therapy for patients with RCDII - a pilot study | ||
Medical condition: Refractory celiac disease type II | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004063-36 | Sponsor Protocol Number: CELIM-RCD-002 | Start Date*: 2016-02-22 |
Sponsor Name:Celimmune LLC | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Type II Refractory Celiac Disease, an In Situ Sm... | ||
Medical condition: Type II Refractory Celiac Disease (RCD-II) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) NL (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-003647-19 | Sponsor Protocol Number: CELIM-NRCD-001 | Start Date*: 2016-02-22 |
Sponsor Name:Celimmune LLC | ||
Full Title: A Phase 2a, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of AMG 714 in Adult Patients with Celiac Disease. | ||
Medical condition: Celiac disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003450-28 | Sponsor Protocol Number: CL009_282 | Start Date*: 2007-09-04 | |||||||||||
Sponsor Name:ChemoCentryx, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Testing CCX282-B in the Treatment of Celiac Disease | |||||||||||||
Medical condition: Celiac Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-000459-35 | Sponsor Protocol Number: TMB01-301 | Start Date*: Information not available in EudraCT |
Sponsor Name:Timber Pharmaceuticals, LLC | ||
Full Title: Protocol Title: The ASCEND Study: A Phase III, Multicenter, Double Blinded Vehicle Controlled Study of TMB-001 - with a Parallel Optional Maximal Use Arm - in the Treatment of RXLI (Xlinked) or ARC... | ||
Medical condition: Congenital ichthyosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Ongoing) FR (Ongoing) IT (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.